S A Bustin1, V G Gyselman, S Siddiqi, S Dorudi. 1. Academic Department of Surgery, St. Bartholomew's, Royal London School of Medicine and Dentistry, London, England. s.a.bustin@mds.qmw.ac.uk
Abstract
BACKGROUND: The clinical benefit of using reverse transcription polymerase chain reaction (RT-PCR)-based assays to detect circulating tumour cells during post-operative surveillance of cancer patients remains unclear. Cytokeratin 20 has been proposed as a tissue-specific marker for the detection of micrometastases in the blood of colorectal cancer patients. However, recent reports have challenged its specificity, and hence the validity of its use. AIMS: The aim of this study was to evaluate the tissue-specificity of ck20 mRNA transcription and its use for detecting circulating colon epithelial cells. PATIENTS AND METHODS: RNA was isolated from the peripheral blood of 51 colorectal cancer patients, four patients with benign gastrointestinal disease and 42 healthy controls. In addition, it was prepared from 32 colorectal cancers, from a pituitary cancer, from normal kidney, liver, fibroblasts, keratinocytes and from 24 lymph nodes obtained from eight patients with benign gastrointestinal disease. Real-time RT-PCR assays were used to quantitative and compare ck20 transcription. RESULTS: Significant levels of ck20 mRNA were detected in all 42 blood samples from healthy volunteers and in all pre- and post-operative blood samples from colorectal cancer patients regardless of the presence of metastatic disease. It was also detected in all other mRNA samples analysed. CONCLUSION: The lack of colon tissue-specificity renders ck20 useless as a marker for the post-operative surveillance of colorectal cancer patients.
BACKGROUND: The clinical benefit of using reverse transcription polymerase chain reaction (RT-PCR)-based assays to detect circulating tumour cells during post-operative surveillance of cancerpatients remains unclear. Cytokeratin 20 has been proposed as a tissue-specific marker for the detection of micrometastases in the blood of colorectal cancerpatients. However, recent reports have challenged its specificity, and hence the validity of its use. AIMS: The aim of this study was to evaluate the tissue-specificity of ck20 mRNA transcription and its use for detecting circulating colon epithelial cells. PATIENTS AND METHODS: RNA was isolated from the peripheral blood of 51 colorectal cancerpatients, four patients with benign gastrointestinal disease and 42 healthy controls. In addition, it was prepared from 32 colorectal cancers, from a pituitary cancer, from normal kidney, liver, fibroblasts, keratinocytes and from 24 lymph nodes obtained from eight patients with benign gastrointestinal disease. Real-time RT-PCR assays were used to quantitative and compare ck20 transcription. RESULTS: Significant levels of ck20 mRNA were detected in all 42 blood samples from healthy volunteers and in all pre- and post-operative blood samples from colorectal cancerpatients regardless of the presence of metastatic disease. It was also detected in all other mRNA samples analysed. CONCLUSION: The lack of colon tissue-specificity renders ck20 useless as a marker for the post-operative surveillance of colorectal cancerpatients.
Authors: Giuliana Giribaldi; Simone Procida; Daniela Ulliers; Franca Mannu; Roberta Volpatto; Giorgia Mandili; Laura Fanchini; Oscar Bertetto; Gianruggero Fronda; Luigi Simula; Elena Rimini; Giovanni Cherchi; Lisa Bonello; Milena Maria Maule; Francesco Turrini Journal: J Mol Diagn Date: 2006-02 Impact factor: 5.568
Authors: Nadia Dandachi; Marija Balic; Stefanie Stanzer; Michael Halm; Margit Resel; Thomas Anton Hinterleitner; Hellmut Samonigg; Thomas Bauernhofer Journal: J Mol Diagn Date: 2005-11 Impact factor: 5.568
Authors: Robert D Loberg; Yaron Fridman; Brian A Pienta; Evan T Keller; Laurie K McCauley; Russell S Taichman; Kenneth J Pienta Journal: Neoplasia Date: 2004 Jul-Aug Impact factor: 5.715
Authors: J Harder; V Engelstaedter; H Usadel; S Lassmann; M Werner; P Baier; F Otto; M Varbanova; E Schaeffner; M Olschewski; H E Blum; O G Opitz Journal: Br J Cancer Date: 2009-01-13 Impact factor: 7.640